Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
30 - From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
from Section 3 - Alzheimer’s Disease Clinical Trials
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
The chapter explores whether high-income countries are ready for the first disease-modifying Alzheimer’s disease (AD) treatment, approved in the USA in February 2021. It looks at the capacity to provide diagnostic services relative to the expected demand, institutional preparedness, and potential solutions to overcome capacity constraints. Wait times are projected to differ substantially. Initial average wait times range from 5 months in Germany to 28 months in Canada. In France, Canada, and Taiwan, we project it will take over a decade to clear the backlog of prevalent cases and to make a treatment accessible with little delay, because of scarcity of dementia specialists, and aggravated by the lack of financial and structural plannin. Potential solutions include broadening the dementia workforce by integration of primary care clinicians and other specialists, care models that leverage specialist time, and telecare-supported models. Better diagnostic technology to detect cognitive decline and the AD pathology in primary care settings and predictive models to triage patients show potential to improve access.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 343 - 353Publisher: Cambridge University PressPrint publication year: 2022
References
Jack, CR, Bennett, DA, Blennow, K, et al. NIA–AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535–62.CrossRefGoogle Scholar
Petersen, RC, Lopez, O, Armstrong, MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation subcommittee of the American Academy of Neurology. Neurology 2018; 90: 126–35.CrossRefGoogle Scholar
Liu, JL, Hlávka, JP, Hillestad, R, Mattke, S. Assessing the Preparedness of the U.S. health care system infrastructure for an Alzheimer’s treatment. Available at: www.rand.org/pubs/research_reports/RR2272.html (accessed July 9, 2021).Google Scholar
Hlavka, JP, Mattke, S, Liu, JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer’s treatment. Rand Health Q 2019; 8: 2.Google ScholarPubMed
Hebert, LE, Weuve, J, Scherr, PA, Evans, DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013; 80: 1778–83.CrossRefGoogle ScholarPubMed
Sado, M, Ninomiya, A, Shikimoto, R, et al. The estimated cost of dementia in Japan, the most aged society in the world. PLoS One 2018; 13: e0206508.Google Scholar
Lang, L, Clifford, A, Wei, L, et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open 2017; 7: e011146.CrossRefGoogle ScholarPubMed
Sperling, RA, Rentz, DM, Johnson, KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6: 228fs13.Google Scholar
Baxi, SM, Girosi, F, Liu, JL. Assessing the preparedness of the Australian health care system infrastructure for an Alzheimer’s disease-modifying therapy. Available at: www.rand.org/pubs/research_reports/RR2891.html (accessed July 9, 2021).Google Scholar
Liu, JL, Hlavka, JP, Coulter, DT, et al. Assessing the preparedness of the Canadian health care system infrastructure for an Alzheimer’s treatment. Available at: www.rand.org/pubs/research_reports/RR2744.html (accessed July 9, 2021).Google Scholar
Mattke, HJ, Yoong, J, Wang, M, Goto, R. Assessing the preparedness of the Japanese health care system infrastructure for an Alzheimer’s treatment. Available at: https://cesr.usc.edu/sites/default/files/CESR%202019-101.pdf (accessed July 9, 2021) .Google Scholar
Hankyung Jun, SKC, Yoong, J, Mattke, S. Assessing the preparedness of the Korean healthcare system infrastructure for an Alzheimer’s treatment. Available at: https://cesr.usc.edu/sites/default/files/Korea_Infrastructure_Projection_final.pdf (accessed July 9, 2021) .Google Scholar
Hankyung Jun, SKC, Yoong, J, Mattke, S. Assessing the preparedness of the Taiwanese healthcare system infrastructure for an Alzheimer’s treatment. Available at: https://cesr.usc.edu/sites/default/files/Taiwan_Infrastructure_Projection_final.pdf (accessed July 9, 2021).Google Scholar
Ritchie, CW, Russ, TC, Banerjee, S, et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease. Alzheimers Res Ther 2017; 9: 85.Google Scholar
Martínez-Lagea, P, Martín-Carrascob, M, Arrietad, E, Rodrigof, J, Formigac, F. Map of Alzheimer’s disease and other dementias in Spain. MapEA Project. Rev Esp Geriatr Gerontol 2018; 53: 26–37.Google Scholar
Jun, H, Cho, SK, Aliyev, ER, Mattke, S, Suen, S-C. How much value would a treatment for Alzheimer’s disease offer? Cost-effectiveness thresholds for pricing a disease-modifying therapy. Curr Alzheimer Res 2020; 17 : 819–22.Google ScholarPubMed
Mattke, S, Cho, SK, Bittner, T, Hlavka, J, Hanson, M. Blood-based biomarkers for Alzheimer’s pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times. Alzheimers Dement (Amst) 2020; 12: e12081.Google ScholarPubMed
Ngandu, T, Lehtisalo, J, Solomon, A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385: 2255–63.CrossRefGoogle Scholar
Rabinovici, GD, Gatsonis, C, Apgar, C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321: 1286–94.CrossRefGoogle ScholarPubMed
Russell-Babin, K, Wurmser, T. Transforming care through top-of-license practice. Nurs Manage 2016; 47: 24–8.CrossRefGoogle Scholar
Mattke, S, Hoch, E. Borrowing for the cure. Available at: www.rand.org/pubs/perspectives/PE141.html (accessed July 9, 2021).Google Scholar
Lam, J, Jun, H, Cho, S K, Hanson, M, Mattke, S. Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer’s disease treatment. Alzheimers Dement (Amst) 2021; 13: e12159.Google Scholar
Greaves, I, Greaves, N, Walker, E, et al. Gnosall Primary Care Memory Clinic: eldercare facilitator role description and development. Dementia (London) 2015; 14: 389–408.CrossRefGoogle ScholarPubMed
Engedal, K, Gausdal, M, Gjora, L, Haugen, PK. Assessment of dementia by a primary health care dementia team cooperating with the family doctor: the Norwegian model. Dement Geriatr Cogn Disord 2012; 34: 263–70.Google Scholar
Lee, L, Hillier, LM, Heckman, G, et al. Primary care-based memory clinics: expanding capacity for dementia care. Can J Aging 2014; 33: 307–19.CrossRefGoogle ScholarPubMed
Alzheimer’s Association. The Alzheimer’s and Dementia Care ECHO® Program. Available at: www.alz.org/professionals/professional-providers/echo-alzheimers-dementia-care-program (accessed June 6, 2019).Google Scholar
Lam, J, Hlávka, J, Mattke, S. The potential emergence of disease-modifying treatments for Alzheimer disease: the role of primary care in managing the patient journey. J Am Board Fam Med 2019; 32: 931–40.CrossRefGoogle ScholarPubMed
Palmqvist, S, Janelidze, S, Stomrud, E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol 2019; 76: 1060–9.CrossRefGoogle ScholarPubMed
Palmqvist, S, Janelidze, S, Quiroz, YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020; 324: 772.CrossRefGoogle ScholarPubMed
Kourtis, LC, Regele, OB, Wright, JM, Jones, GB. Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity. NPJ Digit Med 2019; 2: 9.Google Scholar
Buegler, M, Harms, RL, Balasa, M, et al. Digital biomarker-based individualized prognosis for people at risk of dementia. Alzheimers Dement (Amst) 2020; 12: e12073.Google Scholar
Biogen. Biogen to launch pioneering study to develop digital biomarkers of cognitive health using apple watch and iphone [press release]. Available at: https://investors.biogen.com/news-releases/news-release-details/biogen-launch-pioneering-study-develop-digital-biomarkers (accessed January 2021).Google Scholar
Arnett, DK, Blumenthal, RS, Albert, MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. J Am Coll Cardiol 2019; 74: e177–232.Google Scholar
Progetto Interceptor. Interceptor: the project. Available at: www.interceptorproject.com/en/lo-studio-interceptor/ (accessed July 9, 2021).Google Scholar
Belleville, S, Leblanc, AC, Kergoat, M-J, et al. The Consortium for the early identification of Alzheimer’s disease – Quebec (CIMA-Q). Alzheimers Dement (Amst) 2019; 11: 787–96.Google Scholar
Janelidze, S, Mattsson, N, Palmqvist, S, et al. Plasma p-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 2020; 26: 379–86.Google Scholar
Mattke, S, Klautzer, L, Mengistu, T. Medicines as a service. Available at: www.rand.org/pubs/occasional_papers/OP381.html (accessed July 9, 2021).Google Scholar
- 1
- Cited by